Denali Therapeutics has raised more than $248 million in its stock market debut, marking the largest biotech IPO of the year. The company will use the cash to support work on its experimental drugs for Parkinson’s disease and other neurodegenerative disorders.... Read more »
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too.
The FDA will... Read more »
Gilead Sciences is deepening its capabilities in cell therapy with a deal valued at up to $567 million to acquire Cell Design Labs, a company that discovers and develops such treatments.
The announcement late Thursday comes a little more than four... Read more »
Rahul Chaturvedi worked for 16 years as a life sciences company executive, but he was also an avid consumer tech fan who chafed at the clunky enterprise apps used in his industry. Spoiled by speedy, user-friendly consumer apps, he also wondered... Read more »
Healthcare investment giant OrbiMed Advisors has been described as a workplace enveloped in a toxic culture of sexual harassment, according to an investigation by Stat released late Tuesday.
OrbiMed managing partner and co-founder Samuel Isaly is the main perpetrator of frequent... Read more »
How do you disrupt an industry that markets itself as the embodiment of “forever?”
You bring it back to basics, says Lindsay Reinsmith, co-founder of Ada Diamonds, an online retailer of jewelry with lab-made gemstones in San Francisco. “Science is on... Read more »
On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data, including trials for lung cancer, heart disease, melanoma, Alzheimer’s disease, rare blood disorders, and more. With part two, we’re... Read more »
Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing.
As remarkable as they might seem, however, these medicines... Read more »
Author, investor, and AOL co-founder Steve Case today announced a new $150 million venture fund aimed at pumping investment capital into tech companies in so-called flyover states. Contributing to the fund is an impressive group of some of the most successful... Read more »
The reaction on Wall Street was a little anticlimactic after the FDA approved a new hepatitis B vaccine last month for Berkeley, CA-based Dynavax Technologies (NASDAQ: DVAX).
Many investors sold stock on the news. In the days following the... Read more »
[Updated 12/4/17, 4:48 pm, with CEO comments.] For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
Akili Interactive Labs, a Boston and San Francisco Bay Area... Read more »
Every day, Ashley Barnes straps a battery-powered device onto her waist, legs, and feet, which allows the paraplegic to stand up from her wheelchair and go for walks with the help of crutches. The wearable brace has motors located at Barnes’s... Read more »
Many of biotech’s biggest stories in 2017 followed the highly anticipated data from clinical studies. There were monumental successes, like the first-ever approval of a genetically modified living cell therapy, the first FDA application for a gene therapy or a... Read more »